Search | Clinical Trials Finder

Conditions: Lymphangioleiomyomatosis
Interventions: Imatinib Mesylate 400Mg Capsule, Placebo - Capsule; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New York, New York • Charleston, South Carolina

Conditions: Exercise Performance, Exercise Recovery, Cognitive Function, Nitric Oxide, Blood Flow, Endurance Exercise
Interventions: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation, Placebo, 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Subjects
Interventions: LX4211 400 mg, canagliflozin 300 mg, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Droxidopa+Carbidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Ureteral Calculi
Interventions: celecoxib, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Onychomycosis
Interventions: Albaconozole, Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Atrial Fibrillation
Interventions: Dronedarone, Placebo (for Dronedarone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 51 more

Conditions: Rheumatoid Arthritis
Interventions: SKI-O-703, Placebo; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Beverly Hills, California • Upland, California • Miami Lakes, Florida + 9 more

Conditions: COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions: Hydroxychloroquine Sulfate, Ascorbic Acid; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 943 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 8
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Colorectal Neoplasms, Neoplasm Metastasis
Interventions: Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 87
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more

Conditions: Low Bone Mass
Interventions: Resveratrol, Placebo; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions: Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Gemcitabine, Nab paclitaxel, Proglumide, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Preterm Birth
Interventions: oral micronized progesterone, Identical Placebo tablet; Drug
Lead sponsor: Fetal Medicine Foundation; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Cardiac Toxicity
Interventions: Moxifloxacin; Drug
Lead sponsor: Haiyan Li; Other
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Hypogammaglobulinemia, Lung Transplantation
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: SARS-CoV-2 Infection
Interventions: Hydroxychloroquine sulfate &Azithromycin, Placebo; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 20 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Premature Ejaculation
Interventions: IX-01 400 mg, Placebo, IX-01 800 mg, IX-01 1200 mg; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 29
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 25 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions: Placebo, Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more

Conditions: Overweight and Obesity
Interventions: Citrus flavonone-O-glycosides- LD, Citrus flavonone-O-glycosides- HD, Placebo; Dietary Supplement
Lead sponsor: Vedic Lifesciences Pvt. Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Atopic Dermatitis
Interventions: Placebo Comparator, ASLAN004; Drug · Biological
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 47
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 36 more

Conditions: Depressive Episode, Bipolar 1 Depression
Interventions: SEP-4199 200 mg, SEP-4199 400 mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 4 more

Conditions: Diabetic Macular Edema
Interventions: Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo; Drug · Other
Lead sponsor: Rezolute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more

Search by objective public record fields.

LAM Pilot Study With Imatinib Mesylate

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

Celecoxib (Celebrex) in the Management of Acute Renal Colic

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Oral Progesterone for Prevention of Preterm Birth

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Asymptomatic COVID-19 Trial

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)